Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

IMMUNODEFICIENCY DISORDERS

Complement inhibitor for therapy of CHAPLE

A new study shows successful immunotherapy of a detrimental gastrointestinal disease using the complement inhibitor eculizumab.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1: Activation and regulation of complement pathways.

References

  1. Ozen, A. et al. Nat. Immunol. https://doi.org/10.1038/s41590-020-00830-z (2021).

  2. Ozen, A. et al. N. Engl. J. Med. 377, 52–61 (2017).

    CAS  Article  Google Scholar 

  3. Kurolap, A. et al. N. Engl. J. Med. 377, 87–89 (2017).

    Article  Google Scholar 

  4. Lintner, K. E. et al. Front. Immunol. 7, 36 (2016).

    Article  Google Scholar 

  5. Barnum, S. & Schein, T. (eds.) The Complement FactsBook 2nd edn (Academic Press, 2018).

  6. Lublin, D. M. & Atkinson, J. P. Annu. Rev. Immunol. 7, 35–58 (1989).

    CAS  Article  Google Scholar 

  7. Dho, S. H., Lim, J. C. & Kim, L. K. Immune Netw. 18, e11 (2018).

    Article  Google Scholar 

  8. Lachmann, P. J. Immunol. Today 12, 312–315 (1991).

    CAS  Article  Google Scholar 

  9. Ekdahl, K. N. et al. Immunol. Rev. 274, 245–269 (2016).

    CAS  Article  Google Scholar 

  10. Savelli, S. L. et al. Front. Immunol. 10, 885 (2019).

    CAS  Article  Google Scholar 

  11. Mulvihill, E. et al. Lupus Sci. Med. 6, e000333 (2019).

    Article  Google Scholar 

  12. Kamitaki, N. et al. Nature 582, 577–581 (2020).

    CAS  Article  Google Scholar 

Download references

Acknowledgements

The authors are supported by a National Institute of Arthritis Musculoskeletal and Skin Disease grant (R01 AR073311) from the National Institutes of Health.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Chack-Yung Yu or Stacy P. Ardoin.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Yu, CY., Ardoin, S.P. Complement inhibitor for therapy of CHAPLE. Nat Immunol 22, 106–108 (2021). https://doi.org/10.1038/s41590-020-00842-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41590-020-00842-9

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing